A proposed class action filed Thursday in Manhattan federal court accused Pfizer Inc. of misleading consumers about the health risks associated with the over-the-counter heartburn medicine Zantac.

The lawsuit targeted the New York-based drugmaker over its former production of the medicine, which includes NDMA, an organic chemical that has been linked to certain forms of cancer. According to the filing, Pfizer manufactured Zantac from 2000 to 2006, but never listed NDMA as an ingredient or disclosed the chemical’s cancer-causing properties.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]